Protein / target
Macrophage-stimulating protein receptor
Protein at a glance
Biological role
Transmembrane receptor protein tyrosine kinase
Strongest disease association
Nasopharyngeal Neoplasms
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand.
View complete UniProt function annotationHide complete annotation
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand
Subcellular location
Domains and Gene Ontology detail (26)Hide
Domains & features
Gene Ontology
- Ccell surface
- Cplasma membrane
- Creceptor complex
- Cstress fiber
- Cvacuole
- FATP binding
- Fenzyme binding
- Fmacrophage colony-stimulating factor receptor activity
- Ftransmembrane receptor protein tyrosine kinase activity
- Pcell migration
- Pcell surface receptor protein tyrosine kinase signaling pathway
- Pdefense response
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Receptor tyrosine kinase signalling
- ·Receptor tyrosine kinase that transduces signals from the extracellular matrix into the…
- ·transmembrane receptor protein tyrosine kinase activity
- ·cell surface receptor protein tyrosine kinase signaling pathway
Cell proliferation & survival
- ·Receptor tyrosine kinase that transduces signals from the extracellular matrix into the…
- ·positive regulation of cell population proliferation
Cell migration
- ·Receptor tyrosine kinase that transduces signals from the extracellular matrix into the…
- ·cell migration
Immune signalling
- ·Receptor tyrosine kinase that transduces signals from the extracellular matrix into the…
- ·innate immune response
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Macrophage-stimulating protein receptor inhibitor
Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene MST1R
Gene-level evidence surfaced through the gene MST1Rthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
4 compounds recorded · 1 approved · 3 in clinical development
View all recorded compounds (4)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Supported
Antibodies — Strong
Protein degraders — Emerging
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationLorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
- New publicationBrigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
- Safety communication
Drug Safety Update: Crizotinib (Xalkori▼): risk of cardiac failure
- New publicationFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer.
- Regulatory approval
Approval: Xalkori (EMA)
- New publicationROS1 rearrangements define a unique molecular class of lung cancers.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.